Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL270966 | 0.73 | — | — | |
| SCHEMBL17831029 | 0.71 | — | — | |
| SCHEMBL2098372 | 0.71 | — | — | |
| SCHEMBL14478767 | 0.71 | — | — | |
| SCHEMBL2460808 | 0.71 | TDP1 (0.35) | TDP1 | |
| SCHEMBL12162710 | 0.69 | TDP1 (0.33) | TDP1 | |
| SCHEMBL2107930 | 0.69 | — | — | |
| SCHEMBL1128525 | 0.69 | CA1 (0.36) | — | |
| SCHEMBL2109214 | 0.69 | — | — | |
| SCHEMBL28281447 | 0.67 | TDP1 (0.32) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216736-A2 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100056466-A1 | 2'-Cyanopyrimidine Nucleoside Compound | MATSUDA, AKIRA (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2045256-A1 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20080096830-A1 | Anti-Inflammatory Macrolide Conjugates | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2008-04-24 | — | — | US | disclosed |
| US-7157433-B2 | Compounds, compositions as carriers for steroid/nonsteroid anti-inflammatory; antienoplastic and antiviral active molecules | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB (HR) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216736-A2 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | NUDT1, DPYD, SLC29A1 | TDP1 775/4885 |
| US-20080096830-A1 | Anti-Inflammatory Macrolide Conjugates | NLRP3, IL1B, MPO | TDP1 3121/4885 |
| US-20100056466-A1 | 2'-Cyanopyrimidine Nucleoside Compound | NUDT1, DPYD, SLC29A1 | TDP1 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.